Get the Stockscreener App
11.47
3.29%
-0.39
Arvinas Inc stock is traded at $11.47, with a volume of 922.20K.
It is down -3.29% in the last 24 hours and down -1.63% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$11.86
Open:
$11.86
24h Volume:
922.20K
Relative Volume:
0.46
Market Cap:
$736.65M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-2.4561
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
-5.67%
1M Performance:
-1.63%
6M Performance:
+45.19%
1Y Performance:
-39.28%
1-Day Range:
$11.37
$11.86
1-Week Range:
$11.37
$12.08
52-Week Range:
$5.90
$21.00
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
11.47 | 761.70M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Aug Closing: Is Arvinas Inc stock ready for breakoutEntry Point & Consistent Return Investment Signals - moha.gov.vn
(ARVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN
Arvinas announces preclinical data for ARV-393 - MSN
Can Arvinas Inc. stock sustain institutional interestMarket Movement Recap & Real-Time Chart Pattern Alerts - Улправда
Will Arvinas Inc. stock remain a Wall Street favoriteMarket Movers & Fast Gaining Stock Reports - DonanımHaber
Will Arvinas Inc. stock deliver better than expected guidanceEarnings Recap Report & Reliable Volume Spike Alerts - Улправда
Price Action: Why Arvinas Inc. stock remains on buy listsExit Point & Trade Opportunity Analysis - Улправда
(ARVN) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Possible Bearish Signals With Arvinas Insiders Disposing Stock - simplywall.st
Barclays maintains Arvinas (ARVN) overweight recommendation - MSN
Barclays Raises Price Target for Arvinas (ARVN) to $18 | ARVN St - GuruFocus
Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN - MarketBeat
Armistice Capital LLC Invests $4.12 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Velan Capital Investment Management LP Takes Position in Arvinas, Inc. $ARVN - MarketBeat
Diadema Partners LP Invests $710,000 in Arvinas, Inc. $ARVN - MarketBeat
Arvinas reveals promising preclinical data for ARV-393 - MSN
Arvinas Reveals Promising Preclinical Data for ARV-393 - TipRanks
Arvinas, Inc. Announces Preclinical Data for ARV-393 Combination - TradingView
22NW LP Acquires Shares of 413,533 Arvinas, Inc. $ARVN - MarketBeat
Arvinas (ARVN) Reveals Promising Preclinical Data for Cancer Tre - GuruFocus
Published on: 2025-12-06 23:24:37 - BỘ NỘI VỤ
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - The Manila Times
Arvinas, Inc. Announces Phase 1 Clinical Trial Initiation for ARV-393 Plus Glofitamab in Diffuse Large B-Cell Lymphoma Following Promising Preclinical Data - Quiver Quantitative
Why Arvinas Inc. stock could benefit from AI revolutionProfit Target & AI Forecasted Stock Moves - Newser
Franklin Resources Inc. Grows Stake in Arvinas, Inc. $ARVN - MarketBeat
Why Arvinas Inc. stock is considered a top pickBear Alert & Momentum Based Trading Signals - Newser
ARVN: Robust clinical pipeline advances and strong cash position support growth into 2028 - TradingView
Will Arvinas Inc. stock continue upward momentumIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Arvinas (ARVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How the Narrative Around Arvinas Is Shifting Amid Strategic Moves and Analyst Uncertainty - Yahoo Finance
52,980 Shares in Arvinas, Inc. $ARVN Acquired by SG Americas Securities LLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN - The National Law Review
New Highs: Why Arvinas Inc. stock remains on buy listsJuly 2025 Update & Accurate Intraday Trade Tips - moha.gov.vn
Entropy Technologies LP Purchases Shares of 32,491 Arvinas, Inc. $ARVN - MarketBeat
Arvinas Inc Stock Analysis and ForecastLow Beta Stocks & Outstanding Investment Returns - earlytimes.in
Published on: 2025-11-27 09:33:44 - BỘ NỘI VỤ
Arvinas (Nasdaq: ARVN) plans fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Arvinas to present vepdegestrant breast cancer data at SABCS By Investing.com - Investing.com Nigeria
Arvinas to present vepdegestrant breast cancer data at SABCS - Investing.com
Arvinas, Inc. Announces Multiple Abstract Presentations on Vepdegestrant at San Antonio Breast Cancer Symposium 2025 - Quiver Quantitative
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development ... - Enidnews.com
Arvinas Announces Data Presentations from the Vepdegestrant - GlobeNewswire
Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating (NASDAQ:ARVN) - Seeking Alpha
Arvinas (NASDAQ: ARVN) showcases vepdegestrant breast cancer data at 2025 SABCS - Stock Titan
Promising Biotech Stocks To ConsiderNovember 18th - MarketBeat
Can Arvinas Inc. stock beat market expectations this quarterTrend Reversal & Fast Exit/Entry Strategy Plans - newser.com
Arvinas (NASDAQ:ARVN) Stock Price Down 7%Should You Sell? - MarketBeat
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arvinas Inc Stock (ARVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morrison Briggs | Director |
Sep 22 '25 |
Buy |
7.57 |
30,000 |
227,010 |
76,021 |
| Saik Andrew | Chief Financial Officer |
Jun 24 '25 |
Sale |
7.61 |
5,700 |
43,377 |
164,401 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):